Literature DB >> 24474540

Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors.

Cavit Ceylan1, Omer G Doluoglu, Ibrahim Keleş, Eymen Gazel, Tülay Temuçin, Öner Odabaş, Mustafa Karalar.   

Abstract

INTRODUCTION: To research the importance of the neutrophil-to-lymphocyte ratio (NLR) in muscle-invasive bladder cancers (MIBC) and non-muscle invasive bladder cancer (NMIBC).
METHODS: Data of 198 patients who underwent TUR-TM in our clinic were retrospectively evaluated. Patients were divided into two groups: group-I (MIBC) and group-II (NMIBC). The neutrophil and lymphocyte counts, NLR, hemoglobin and hematocrit values, tumor numbers, sizes and degrees of patients were recorded. Within the inter-group comparison, Mann-Whitney U test was used for the values stated with measuring, whereas a Chi-square test was used for the values stated with counting. The cut-off value for the NLR was determined with ROC curve.
RESULTS: The NLR values of group-I and group-II were found as 4.14 ± 2.76 and 3.36 ± 2.88, respectively (p = 0.03). Whether the NLR carries a differential property was evaluated with ROC curve. The cut-off value was estimated as 3.96 according to the Youden index. With this value, sensitivity was found as 50%, specificity was 22.8% and AUC was 0.615 (p = 0.03). DISCUSSION: According to the data in this study, it can be said that Ta-T1 tumors are likely to be invasive by 50% if the NLR value is greater than 3.96.

Entities:  

Mesh:

Year:  2013        PMID: 24474540     DOI: 10.5301/uro.5000031

Source DB:  PubMed          Journal:  Urologia        ISSN: 0391-5603


  8 in total

1.  Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer.

Authors:  Mehmet Emin Ozyalvacli; Gulzade Ozyalvacli; Ramazan Kocaaslan; Kursat Cecen; Ugur Uyeturk; Eray Kemahlı; Adnan Gucuk
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

2.  Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer.

Authors:  Özgür Efiloğlu; Banu İşbilen Başok; Turgay Turan; Tuncay Toprak; Bülent Erol; Turhan Çaşkurlu; Asıf Yıldırım
Journal:  Turk J Urol       Date:  2020-02-07

3.  Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.

Authors:  Eric Ojerholm; Andrew Smith; Wei-Ting Hwang; Brian C Baumann; Kai N Tucker; Seth P Lerner; Ronac Mamtani; Ben Boursi; John P Christodouleas
Journal:  Cancer       Date:  2016-10-27       Impact factor: 6.860

Review 4.  Immunotherapy in urothelial carcinoma: fade or future standard?

Authors:  Johannes Breyer; Maximilian Burger; Wolfgang Otto
Journal:  Transl Androl Urol       Date:  2016-10

5.  Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non muscle invasive bladder cancer?

Authors:  Haci Ibrahim Cimen; Fikret Halis; Hasan Salih Saglam; Ahmet Gokce
Journal:  Int Braz J Urol       Date:  2017 Jan-Feb       Impact factor: 1.541

6.  Clinical Value of Postoperative Neutrophil-to-Lymphocyte Ratio Change as a Detection Marker of Bladder Cancer Recurrence.

Authors:  Qingyun Zhang; Qinqiao Lai; Shan Wang; Qinggui Meng; Zengnan Mo
Journal:  Cancer Manag Res       Date:  2021-01-29       Impact factor: 3.989

7.  Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma.

Authors:  Su-Min Lee; Andrew Russell; Giles Hellawell
Journal:  Korean J Urol       Date:  2015-11-03

8.  Preoperative neutrophil-lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer.

Authors:  Chengquan Ma; Bingxin Lu; Chengwen Diao; Kun Zhao; Xinpeng Wang; Baojing Ma; Baojian Lu; Erlin Sun
Journal:  Onco Targets Ther       Date:  2016-08-08       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.